Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea
Authors:
- Viktoria BlumenbergVBViktoria Blumenberg
- Filippo BirocchiFBFilippo Birocchi
- Angela ShihASAngela Shih
- Giulia EscobarGEGiulia Escobar
- Adele MucciAMAdele Mucci
- Alexander ArmstrongAAAlexander Armstrong
- Diana CirsteaDCDiana Cirstea
- Benjamin R. PuliafitoBPBenjamin R. Puliafito
- Tejaswini M. DhawaleTDTejaswini M. Dhawale
Top Cited Papers
- 7 May 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 147 (19) , 2215-2225
Abstract
Intractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma with reported mortality rates of 36% to 50%. The optimal clinical management is unknown. Here, we report a series of 5 patients who presented with severe diarrhea after BCMA CAR T-cell treatment. We hypothesized that the Janus kinase inhibitor, ruxolitinib, might be an effective therapy based on its success in graft-versus-host-disease after allogeneic bone marrow transplant and other immune-driven diarrhea syndromes. Three patients received ruxolitinib, all of whom experienced rapid clinical improvement. Among the 2 patients with matched pretreatment and posttreatment biopsies, both showed signs of histopathologic response, including 1 with CAR T-cell–associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract.Keywords
This publication has 41 references indexed in Scilit:
- Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral bloodCytometry Part B: Clinical Cytometry, 2024
- ARAP1 negatively regulates stress fibers formation and metastasis in lung adenocarcinoma via controlling Rho signalingDiscover Oncology, 2023
- JAK Inhibition with Baricitinib for Severe CVID-Related Enteropathy: a Case ReportJournal of Clinical Immunology, 2023
- Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2022
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Do Long-Lived Plasma Cells Maintain a Healthy Microbiota in the Gut?Trends in Immunology, 2018
- INSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site DistributionsMolecular Therapy - Methods & Clinical Development, 2017
- INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular GenomesMolecular Therapy - Methods & Clinical Development, 2017
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2009